Your preferences have been updated successfully.
Top 30 Lists
Rgenix Announces $33M Series B Financing To Develop First-in-Class Cancer Therapeutics
Rgenix, a cancer therapeutics company developing first-in-class drugs targeting novel cancer pathways, secures $33 Million in Series B Financing to develop cancer therapeutics.
READ FULL INVESTMENT ARTICLE
In this article